gene therapy sarepta - Search News

Order byBest matchMost fresh

News

Sarepta shares crash

· 21h · on MSN

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

Sarepta Therapeutics stock plummeted Monday after the company said a second patient receiving its gene therapy died from liver failure, raising serious questions on the drug’s outlook.Shares fell 40% to $21.

Continue reading

· 16h · on MSN

Sarepta shares crash as second patient dies after receiving its gene therapy

· 17h · on MSN

Second patient death reported with gene therapy for muscular dystrophy

1d

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

1don MSN

Sarepta crashes after second death linked to Roche-partnered Elevidys

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

Managed Healthcare Executive22h

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results